British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 - a rapid update.

Like Comment
The overall aim of the guideline is to provide up-to-date, evidence-based recommendations on the use of biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL12/23p40 (ustekinumab), IL17A (ixekizumab, secukinumab), IL17RA (brodalumab) and IL23p19 (guselkumab, risankizumab, tildrakizumab) in adults, children and young people for the treatment of psoriasis; consideration is given to the specific needs of people with psoriasis and psoriatic arthritis.

Click here to read the full article @ The British journal of dermatology
Go to the profile of ClinOwl


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
2311 Contributions
0 Following

No comments yet.